Langbahn Team – Weltmeisterschaft

Patritumab

Patritumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetHER3
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG

Patritumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator.[1][2]

Clinical trials

It is in a phase 2 clinical trial for squamous cell cancer of the head and neck.[3]

It is to be included in a new arm of the I-SPY 2 breast cancer trial.[4]

References

  1. ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).
  2. ^ Horinouchi H (December 2016). "The prospect of patritumab for treating non-small cell lung cancer". Expert Opinion on Biological Therapy. 16 (12): 1549–1555. doi:10.1080/14712598.2016.1249846. PMID 27744717. S2CID 4035336.
  3. ^ Clinical trial number NCT02633800 for "A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and Neck" at ClinicalTrials.gov
  4. ^ "Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer" (Press release). October 2016.


Quelle: http://en.wikipedia.org/wiki/Patritumab